Vertex, Kissei partner on MAP kinase inhibitors
Executive Summary
In their second agreement, Vertex Pharmaceuticals and Kissei will work together on Vertex's p38 mitogen activated protein (MAP) kinase program for developing new, orally-active drug treatments of inflammatory and neurological diseases.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice